• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


China-Based Adlai Nortye Opens U.S. Headquarters in North Brunswick, New Jersey

Adlai Nortye Ltd., a leading China-based biopharmaceutical company dedicated to the discovery and development of innovative new treatments, officially opened its new USA headquarters at the Biotechnology Development Center in North Brunswick, New Jersey.

According to company officials, the new location marks a significant step in the company's global expansion and follows the recent launch of the company's first international translational medicine laboratory in Boston last month.

Carsten Lu, CEO of Adlai Nortye said: "We are a leading R&D driven pharmaceutical company with a growing staff and a uniquely rich pipeline of late-stage treatments. Today, with the opening of our new US headquarters, Adlai Nortye has taken another major step in our goal to become an international player. We are ready to make greater breakthroughs in the field of immuno-oncology, to make more drugs be successfully approved and marketed."

Dr. Lars Birgerson, CDO, President & CEO of Adlai Nortye USA said of the recent expansion and choice of location "Where better to build a US HQ than New Jersey, the heart of the American pharmaceutical industry. The location is especially perfect as it will also provide us with an opportunity to combine our US HQ and development center with our antibody research group here in the science park."

The U.S. pharmaceutical market remains the most important national market globally, accounting for over 45% of the global pharmaceutical market with a value of USD 446 billion dollars. The new US headquarters in New Jersey will be the global center from where we will coordinate our Development programs worldwide.

The company said this latest advancement follows a string of recent international milestones for the company which has been steadily expanding over the past year, including raising $53 million in Series B Round of financing.

Other announcements include obtaining exclusive, development and commercialization rights to Pelareorep in Mainland China, Hong Kong, Macau, Singapore, South Korea and Taiwan from Oncolytics.The forming of a strategic partnership with Eisai and exclusive worldwide development and sales rights of EP4, excluding Japan and part of Asia outside Mainland China. And, signing of a partnership deal with Novartis to acquire exclusive global development, production and sales rights to Buparlisib.

Exclusive Research